Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy

In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with (n = 112) and without (n = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes.

Download Full-text

Whole-exome sequencing identifies biosignatures that predict adverse survival outcomes in surgically treated patients with oral cavity squamous cell carcinoma

Oral Oncology ◽

10.1016/j.oraloncology.2021.105547 ◽

2021 ◽

Vol 122 ◽

pp. 105547

Author(s):

Chun-Ta Liao ◽

Lan-Yan Yang ◽

Li-Yu Lee ◽

Chien-Yu Lin ◽

Hung-Ming Wang ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Cavity ◽

Cell Carcinoma ◽

Exome Sequencing ◽

Whole Exome Sequencing ◽

Squamous Cell ◽

Survival Outcomes ◽

Whole Exome

Download Full-text

Abstract 3149: Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung

10.1158/1538-7445.am2019-3149 ◽

2019 ◽

Author(s):

Kazue Yoneda ◽

Taiji Kuwata ◽

Masataka Mori ◽

Masatoshi Kanayama ◽

Ayako Hirai ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Neutrophil To Lymphocyte Ratio ◽

Prognostic Impact ◽

Lymphocyte Ratio

Download Full-text

Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis

Journal of Otolaryngology - Head and Neck Surgery ◽

10.1186/1916-0216-42-30 ◽

2013 ◽

Vol 42 (1) ◽

pp. 30 ◽

Cited By ~ 42

Author(s):

Han Zhang ◽

Peter T Dziegielewski ◽

Vince L Biron ◽

Jacek Szudek ◽

Khaled H Al-Qahatani ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Cavity ◽

Cell Carcinoma ◽

Squamous Cell ◽

Multimodal Therapy ◽

Institutional Analysis ◽

Survival Outcomes

Download Full-text

Prospective Evaluation of XRCC-1 as a Biopredictor for Survival Outcomes in Patients of Head and Neck Squamous Cell Carcinoma (HNSCC): A Meta-analysis

10.21203/rs.3.rs-698406/v1 ◽

2021 ◽

Author(s):

Fan Yang ◽

Liu-qing Zhou ◽

Yan-jun Wang

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Meta Analysis ◽

Epidemiologic Studies ◽

Neck Squamous Cell Carcinoma ◽

Survival Outcomes ◽

Prognostic Impact ◽

Meta Analyses

Abstract Background: Epidemiologic studies have demonstrated that X-ray repair cross-complementary group 1 (XRCC1) is one of the susceptibility factors in head and neck squamous cell carcinoma(HNSCC) patients. However, its clinical prognostic impact remains controversial. Thus, a meta-analysis was performed to clarify the survival value of XRCC1 in HNSCC patients.Methods: Following the Preferred Reporting Items or Systematic Reviews Meta Analyses (PRISMA) 2020 guidelines, literature searches were systematically performed by PubMed, EMBASE and Web of Science with a manual retreive to evaluate the prognostic consequence of XRCC1 in HNSCC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were collected to estimate the correlation between XRCC1 and the survival outcomes of HNSCC patients.Results: Ten studies including 2086 HNSCC patients who satisfied the inclusion and exclusion criteria were included in this meta-analysis. The meta-analysis showed that high XRCC1 expression and Arg399Gln and Arg194Trp were significantly correlated with poorer overall survival (OS), with HRs of 1.97 (95% CI, 1.36–2.84, P<0.001), 1.30 (95% CI, 1.12–1.51, P<0.001), and 1.65 (95% CI, 1.18–2.32 P<0.05), respectively.Conclusion: XRCC1 was associated with poorer survival outcomes in HNSCC patients. Hence, XRCC1 is a potential therapeutic target for HNSCC.

Download Full-text

Prognostic impact of extratumoral perineural invasion in patients with oral cavity squamous cell carcinoma

Cancer Medicine ◽

10.1002/cam4.2392 ◽

2019 ◽

Vol 8 (14) ◽

pp. 6185-6194 ◽

Cited By ~ 1

Author(s):

Li‐Yu Lee ◽

Dante De Paz ◽

Chien‐Yu Lin ◽

Kang‐Hsing Fan ◽

Hung‐Ming Wang ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Cavity ◽

Cell Carcinoma ◽

Squamous Cell ◽

Perineural Invasion ◽

Prognostic Impact

Download Full-text

The prognostic impact of neutrophil to lymphocyte ratio in patients with recurrent or metastatic esophageal squamous cell carcinoma receiving immune checkpoint inhibitors.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.4_suppl.69 ◽

2018 ◽

Vol 36 (4_suppl) ◽

pp. 69-69

Author(s):

Jhe-Cyuan Guo ◽

Chia-Chi Lin ◽

Ta-Chen Huang ◽

Min-Shu Hsieh ◽

Chih-Hung Hsu

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Univariate Analysis ◽

White Blood Cells ◽

Neutrophil To Lymphocyte Ratio ◽

Prognostic Impact ◽

Response Evaluation ◽

Lymphocyte Ratio

69 Background: The study explored the prognostic impacts of clinical parameters including neutrophil to lymphocyte ratio (NLR) in recurrent/metastatic esophageal squamous cell carcinoma (R/M ESCC) patients receiving anti-programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy. Methods: Thirty-eight patients were enrolled. Tumor response evaluation was made according to Response Evaluation Criteria in Solid Tumours 1.1, and the clinical benefit response (CBR) was defined as complete response, partial response or stable disease at least 6 months. Clinical factors were analyzed for their impacts on patients' overall survival (OS) and progression-free survival (PFS). Formalin-fixed, paraffin-embedded tissues from 8 patients were analyzed by NanoString nCounter Human PanCancer Immune Profiling (NanoString Technologies, Seattle, WA, US). Results: Twenty-six recurrent and 12 de novo metastatic ESCC patients were enrolled. The response rate is 11.8%, and the CBR rate was 21.1%. The median PFS and OS are 2.7 and 5.5 months, respectively. The CBR group has lower blood white blood cells (WBC) ( P = 0.029), monocytes (p = 0.003), and NLR (p = 0.005). In univariate analysis, WBC, neutrophils, and NLR were statistically associated with PFS; performance status (PS), disease extent, albumin, WBC, neutrophils, and NLR were statistically associated with OS. In multivariate analysis, NLR (p = 0.007) was statistically associated with PFS; PS (p = 0.029) and NLR (p = 0.050) were statistically associated with OS. On examining the immune-related genes in ESCC tissues’ microenvironment, the ratios of mast cells, neutrophils, and macrophages relative to tumor-infiltrating lymphocytes (TILs) have significantly lower in the CBR group than in the non-CBR group. Conclusions: High NLR was associated with inferior prognosis in R/M ESCC patients receiving anti-PD-1/PD-L1-based therapy. The increased ratio of neutrophil to TILs in the ESCC tumor microenvironment of non-CBR patients may suggest a mechanistic role of neutrophils in affecting the efficacy of anti-PD-1/PD-L1 therapy. (Supported by the grant of MOST 105-2314-B-002 -186 -MY3)

Download Full-text